GRAFORCE
15.5.2023 02:01:27 CEST | Business Wire | Press release
Graforce, Germany’s leading provider of zero carbon hydrogen plants, and Worley, a leading global engineering and project delivery business, are cooperating to scale methane electrolysis (plasmalysis) starting in Australia, Pacific, Asia and China. Plasmalysis is a game changing technology, which converts natural gas, LNG, flare gas and other hydrocarbons into hydrogen without emitting CO2 or any other greenhouse gas into the atmosphere. This allows gas consumers to switch to clean-burning hydrogen without changing their energy supplier or mode of transportation. Graforce and Worley will present plasmalysis plants at APPEA 2023 in Adelaide, Australia (15-18 May) at the Worley sponsored Hydrogen Pavilion showcasing latest innovations in the hydrogen industry and its impact on decarbonization of industries and fossil fuels.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230514005004/en/
Methane Plasmalysis plants – graphics shows a 12 MW plant - convert natural gas, LNG, flare gas and other hydrocarbons into hydrogen without emitting carbon dioxide or any other greenhouse gas into the atmosphere. This allows gas consumers to switch to clean-burning hydrogen without changing their energy supplier or way of transportation. (Graphic: Business Wire)
Australia is among the largest producers of natural gas and one of the world's leading fuel suppliers. Projects to supply Germany with LNG and green hydrogen are in progress. At the same time, the country aims to reduce its CO2 emissions by more than 40 percent by 2030. Sustainable technologies like plasmalysis are an essential requirement to meet both, economic and climate targets.
“The entire APAC region is looking for green technologies for existing energy sources to achieve climate targets. The cooperation with Worley is an important step for us to quickly scale our methane plasmalysis and to open up these markets,” said Dr. Jens Hanke, CTO of Graforce.
Worley provides large scale engineering, procurement, and construction services to the energy, resources, and chemicals industries. Worley will provide engineering and project delivery services for plasmalysis plants customers in Australia and Asia. In the modular plants, a high-frequency plasma field generated by renewable electricity splits hydrocarbons such as methane into their molecular components: hydrogen and solid carbon. Compared to water electrolysis, plasmalysis requires only one-fifth the energy to produce the same amount of hydrogen. A single 20-megawatt plant can convert about 70,000 metric tons of methane into hydrogen per year and eliminate about 200,000 metric tons of CO2 emissions.
“As we scale up towards the vast quantities of renewable energy and hydrogen required to meet our Net Zero goals, our medium-term reliance on fossil fuels and in particular, natural gas and LNG, is a given. Plasmalysis marries these two realities together and enables faster decarbonisation utilising existing infrastructure. Plasmalysis is likely to be a valuable tool in the decarbonisation toolbox and contribute to our company purpose of delivering a more sustainable world,” says Gillian Cagney, Worley ANZ Managing Director.
About
Graforce is a German hydrogen technology company. Their power-to-X plants produce carbon dioxide free or carbon dioxide negative hydrogen and synthetic feedstocks – with highest efficiency and lower infrastructure costs in the multi-megawatt range. Thus, Graforce decarbonizes fossil energies, industries and the heat, transport and building sectors. Graforce is currently in the process of expanding its financial and strategic partnerships to quickly scale its hydrogen technology worldwide.
Worley is a global company headquartered in Australia and our purpose is delivering a more sustainable world. Worley is a leading global provider of professional project and asset services in the energy, chemicals and resources sectors. As a knowledge-based service provider, we use our knowledge and capabilities to support our customers to reduce their emissions and move towards a low carbon future. Worley Limited is listed on the Australian Securities Exchange (ASX: WOR).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230514005004/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom